PureTech Health (LON:PRTC) Trading 6.3% Higher – Still a Buy?

Shares of PureTech Health plc (LON:PRTC) rose 6.3% during mid-day trading on Tuesday . The company traded as high as GBX 127 ($1.67) and last traded at GBX 125.40 ($1.65). Approximately 1,234,305 shares traded hands during mid-day trading, an increase of 17% from the average daily volume of 1,059,029 shares. The stock had previously closed at GBX 118 ($1.56).

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 455 ($6.00) price target on shares of PureTech Health in a report on Monday, December 16th.

PureTech Health Price Performance

The company has a market capitalization of £381.56 million, a PE ratio of -5.21 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The stock has a 50 day moving average price of GBX 134.79 and a two-hundred day moving average price of GBX 147.92.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.